Leukemia-drug competitors of Infinity Pharmaceuticals Inc., The Wall Street Journal reported, had strong if incremental releases of scientific data about their products Wednesday. But JPMorgan says investors are “increasingly skittish” ahead of June’s American Society of Clinical Oncology conference, at which Infinity is expected to release safety and tolerability data for its drug. The bank predicts “a good showing” by Infinity but warns it may not be enough to outshine the rivals.
Infinity Pharmaceuticals stock slides
May 17, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢